Kingswood Wealth Advisors LLC Acquires New Holdings in Atyr PHARMA INC (NASDAQ:ATYR)

Kingswood Wealth Advisors LLC bought a new position in shares of Atyr PHARMA INC (NASDAQ:ATYR) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 47,000 shares of the company’s stock, valued at approximately $170,000.

Separately, JPMorgan Chase & Co. boosted its stake in Atyr PHARMA by 52.0% in the third quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company’s stock valued at $55,000 after acquiring an additional 10,754 shares in the last quarter. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Atyr PHARMA Trading Up 3.2 %

NASDAQ ATYR opened at $3.86 on Monday. Atyr PHARMA INC has a 12-month low of $1.42 and a 12-month high of $4.22. The company has a fifty day simple moving average of $3.48 and a two-hundred day simple moving average of $2.69. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02. The stock has a market cap of $324.01 million, a P/E ratio of -4.11 and a beta of 1.08.

Atyr PHARMA (NASDAQ:ATYR) last issued its earnings results on Thursday, November 7th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01). On average, analysts forecast that Atyr PHARMA INC will post -0.91 earnings per share for the current year.

Analyst Upgrades and Downgrades

ATYR has been the topic of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price target on shares of Atyr PHARMA in a research report on Tuesday, December 10th. Cantor Fitzgerald began coverage on Atyr PHARMA in a research report on Monday, January 6th. They set an “overweight” rating on the stock. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Atyr PHARMA has an average rating of “Buy” and a consensus target price of $19.25.

Atyr PHARMA Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.